🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million infections per year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This milestone represents a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Global Access

According to results released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This places it at an equal footing with the typical regimen, which combines two antibiotics. The trial included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Doctors directly involved have expressed positive views. The availability of a single-dose, oral treatment of this kind is described as a "game-changer" for managing the epidemic. This is deemed crucial to reduce the burden of the illness for individuals and to prevent the spread of untreatable gonorrhoea globally.